{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T17:47:16Z","timestamp":1771350436887,"version":"3.50.1"},"reference-count":30,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"3","license":[{"start":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T00:00:00Z","timestamp":1632960000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Archives of Rheumatology"],"abstract":"<jats:p>Objectives: The aim of this study was to investigate the efficacy and safety of anti-interleukin-1 (anti-IL-1) agents and tumor necrosis factor\u2010alpha (TNF-\u03b1) inhibitors in renal transplant patients.\r\nPatients and methods: Between February 2014 and February 2020, data of 12 renal transplant recipients (9 males, 3 females; median age: 51 years; range, 19 to 70 years) who received anti-IL-1 agents or TNF-\u03b1 inhibitors for inflammatory diseases in the post-transplant time period and were followed in a single transplant center (n=12) were retrospectively analyzed. A total of 46 cases were reported in the literature, before the data were collected. The overall outcomes of all cases were analyzed in this study.\r\nResults: Thirty-seven patients received anti-IL-1 agents in the post-transplant period. The main indications for anti-IL-1 agents were familial Mediterranean fever (FMF) and amyloidosis (75.7%). The continuation rate of colchicine treatment in patients with FMF was 85.7%. Anti-IL-1 agents prevented attacks completely in 89.3% of FMF patients. The number of cases used TNF-\u03b1 inhibitors among renal transplant patients was lower (n=21). The TNF-\u03b1 inhibitors were used mainly for inflammatory bowel diseases (57.1%) and ankylosing spondylitis (33.3%) and suppressed the disease activity in most of the patients with inflammatory diseases (72.7%). Death (n=3) and malignancies (n=3) were reported in patients who received TNF-\u03b1 inhibitors, but not in patients who received anti-IL-1. The renal outcomes and graft survival rates were satisfactory in patients who received both anti-IL-1 agents and TNF-\u03b1 inhibitors.\r\nConclusion: Our results support that anti-IL-1 agents can be used effectively and safely in renal transplant patients.<\/jats:p>","DOI":"10.46497\/archrheumatol.2021.8500","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T10:53:42Z","timestamp":1611831222000},"page":"366-374","source":"Crossref","is-referenced-by-count":9,"title":["The use of anti-interleukin-1 agents and tumor necrosis factor\u2010alpha inhibitors in renal transplant recipients"],"prefix":"10.5152","volume":"36","author":[{"family":"Veli Yaz\u0131s\u0131z","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Vural Taner Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"\u0130smail U\u00e7ar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"\u00d6zg\u00fcr Dandin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Bengisu Aslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Funda Erbasan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"H\u00fcseyin Ko\u00e7ak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Mustafa Ender Terzio\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3111","published-online":{"date-parts":[[2021,9,30]]},"reference":[{"key":"ref-1","doi-asserted-by":"crossref","unstructured":"Sarzi-Puttini P, Ceribelli A, Marotto D, Batticciotto A, Atzeni F. Systemic rheumatic diseases: From biological agents to small molecules. Autoimmun Rev 2019;18:583-92.","DOI":"10.1016\/j.autrev.2018.12.009"},{"key":"ref-2","doi-asserted-by":"crossref","unstructured":"Cessak G, Kuzawi\u0144ska O, Burda A, Lis K, Wojnar M, Mirowska-Guzel D, et al. TNF inhibitors - Mechanisms of action, approved and off-label indications. Pharmacol Rep 2014;66:836-44.","DOI":"10.1016\/j.pharep.2014.05.004"},{"key":"ref-3","doi-asserted-by":"crossref","unstructured":"G\u00fcl A. Approach to the patients with inadequate response to colchicine in familial Mediterranean fever. Best Pract Res Clin Rheumatol 2016;30:296-303.","DOI":"10.1016\/j.berh.2016.09.001"},{"key":"ref-4","doi-asserted-by":"crossref","unstructured":"Varan \u00d6, Kucuk H, Babaoglu H, Guven SC, Ozturk MA, Haznedaroglu S, et al. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol 2019;29:363-6.","DOI":"10.1080\/14397595.2018.1457469"},{"key":"ref-5","unstructured":"Tiago Silva J, L\u00f3pez-Medrano F, Aguado JM. Highlights in solid transplant infectious diseases 2015- 2017. Rev Esp Quimioter 2018;31 Suppl 1(Suppl 1):52-5."},{"key":"ref-6","doi-asserted-by":"crossref","unstructured":"Caporali R, Crepaldi G, Codullo V, Benaglio F, Monti S, Todoerti M, et al. 20 years of experience with tumour necrosis factor inhibitors: what have we learned? Rheumatology (Oxford) 2018;57(57 Suppl 7):vii5-vii10.","DOI":"10.1093\/rheumatology\/key059"},{"key":"ref-7","doi-asserted-by":"crossref","unstructured":"Quinn CS, Jorgenson MR, Descourouez JL, Muth BL, Astor BC, Mandelbrot DA. Management of Tumor Necrosis Factor a Inhibitor Therapy After Renal Transplantation: A Comparative Analysis and Associated Outcomes. Ann Pharmacother 2019;53:268-75.","DOI":"10.1177\/1060028018802814"},{"key":"ref-8","doi-asserted-by":"crossref","unstructured":"Trabulus S, Korkmaz M, Kaya E, Seyahi N. Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever. Clin Transplant 2018;32:e13345.","DOI":"10.1111\/ctr.13345"},{"key":"ref-9","doi-asserted-by":"crossref","unstructured":"\u00d6z\u00e7akar ZB, Keven K, \u00c7akar N, Yal\u00e7\u0131nkaya F. Transplantation within the era of anti-IL-1 therapy: case series of five patients with familial Mediterranean fever-related amyloidosis. Transpl Int 2018;31:1181-4.","DOI":"10.1111\/tri.13312"},{"key":"ref-10","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91."},{"key":"ref-11","doi-asserted-by":"crossref","unstructured":"Yildirim T, Yilmaz R, Uzerk Kibar M, Erdem Y. Canakinumab treatment in renal transplant recipients with familial Mediterranean fever. J Nephrol 2018;31:453-5.","DOI":"10.1007\/s40620-018-0475-5"},{"key":"ref-12","doi-asserted-by":"crossref","unstructured":"Kortus-G\u00f6tze B, Hoyer J. Successful renal transplantation in Muckle-Wells syndrome treated with anti-IL-1b-monoclonal antibody. NDT Plus 2011;4:404-5.","DOI":"10.1093\/ndtplus\/sfr118"},{"key":"ref-13","doi-asserted-by":"crossref","unstructured":"Moser C, Pohl G, Haslinger I, Knapp S, Rowczenio D, Russel T, et al. Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. Nephrol Dial Transplant 2009;24:676-8.","DOI":"10.1093\/ndt\/gfn646"},{"key":"ref-14","doi-asserted-by":"crossref","unstructured":"Alpay N, Sumnu A, Cal\u0131skan Y, Yaz\u0131c\u0131 H, T\u00fcrkmen A, G\u00fcl A. Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever. Rheumatol Int 2012;32:3277-9.","DOI":"10.1007\/s00296-010-1474-6"},{"key":"ref-15","doi-asserted-by":"crossref","unstructured":"Hasbal NB, Koc Y, Sevinc M, Unsal A, Basturk T. A familial Mediterranean fever patient with double homozygous mutations treated with anakinra after kidney transplantation. Nefrologia 2020;40:563-4.","DOI":"10.1016\/j.nefro.2019.03.012"},{"key":"ref-16","doi-asserted-by":"crossref","unstructured":"Celebi ZK, Kucuksahin O, Sengul S, Tuzuner A, Keven K. Colchicine-resistant familial Mediterranean fever in a renal transplantation patient: successful treatment with anakinra. Clin Kidney J 2014;7:219-20.","DOI":"10.1093\/ckj\/sft164"},{"key":"ref-17","doi-asserted-by":"crossref","unstructured":"Mulders-Manders CM, Baas MC, Molenaar FM, Simon A. Peri- and Postoperative Treatment with the Interleukin-1 Receptor Antagonist Anakinra Is Safe in Patients Undergoing Renal Transplantation: Case Series and Review of the Literature. Front Pharmacol 2017;8:342.","DOI":"10.3389\/fphar.2017.00342"},{"key":"ref-18","doi-asserted-by":"crossref","unstructured":"Loustau C, Rosine N, Forien M, Ottaviani S, Juge PA, Liot\u00e9 F, et al. Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study. Joint Bone Spine 2018;85:755-60.","DOI":"10.1016\/j.jbspin.2018.03.015"},{"key":"ref-19","doi-asserted-by":"crossref","unstructured":"\u00d6z\u00e7akar ZB, \u00d6zdel S, Y\u0131lmaz S, Kurt-\u015e\u00fck\u00fcr ED, Ekim M, Yal\u00e7\u0131nkaya F. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol 2016;35:441-6.","DOI":"10.1007\/s10067-014-2772-2"},{"key":"ref-20","doi-asserted-by":"crossref","unstructured":"Sendogan DO, Saritas H, Kumru G, Eyupoglu S, Sadioglu RE, Tuzuner A, et al. Outcomes of Canakinumab Treatment in Recipients of Kidney Transplant With Familial Mediterranean Fever: A Case Series. Transplant Proc 2019;51:2292-4.","DOI":"10.1016\/j.transproceed.2019.03.049"},{"key":"ref-21","doi-asserted-by":"crossref","unstructured":"Grupper A, Schwartz D, Baruch R, Schwartz IF, Nakache R, Goykhman Y, et al. Kidney transplantation in patients with inflammatory bowel diseases (IBD): analysis of transplantation outcome and IBD activity. Transpl Int 2019;32:730-8.","DOI":"10.1111\/tri.13415"},{"key":"ref-22","doi-asserted-by":"crossref","unstructured":"Brokalaki EI, Voshege N, Witzke O, Kribben A, Schadendorf D, Hillen U. Treatment of severe psoriasis with etanercept in a pancreas-kidney transplant recipient. Transplant Proc 2012;44:2776-7.","DOI":"10.1016\/j.transproceed.2012.09.008"},{"key":"ref-23","doi-asserted-by":"crossref","unstructured":"Hanset N, Tsevi MY, Duprez T, Ivanoiu A, Devresse A, Demoulin N, et al. Infliximab for relapsing neurosarcoidosis recurring after kidney transplantation: a case report. Acta Clin Belg 2019:1-3.","DOI":"10.1080\/17843286.2019.1664093"},{"key":"ref-24","doi-asserted-by":"crossref","unstructured":"Ozdogan H, Ugurlu S. Familial Mediterranean Fever. Presse Med 2019;48:e61-e76.","DOI":"10.1016\/j.lpm.2018.08.014"},{"key":"ref-25","doi-asserted-by":"crossref","unstructured":"Pascart T, Richette P. Colchicine in Gout: An Update. Curr Pharm Des 2018;24:684-9.","DOI":"10.2174\/1381612824999180115103951"},{"key":"ref-26","doi-asserted-by":"crossref","unstructured":"Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 2016;75:644-51.","DOI":"10.1136\/annrheumdis-2015-208690"},{"key":"ref-27","doi-asserted-by":"crossref","unstructured":"Roldan R, Ruiz AM, Miranda MD, Collantes E. Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. Joint Bone Spine 2008;75:504-5.","DOI":"10.1016\/j.jbspin.2008.04.001"},{"key":"ref-28","doi-asserted-by":"crossref","unstructured":"Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol 2011;38:516-8.","DOI":"10.3899\/jrheum.100718"},{"key":"ref-29","doi-asserted-by":"crossref","unstructured":"Seror R, Mariette X. Malignancy and the Risks of Biologic Therapies: Current Status. Rheum Dis Clin North Am 2017;43:43-64.","DOI":"10.1016\/j.rdc.2016.09.006"},{"key":"ref-30","unstructured":"Pohl C, Hombach A, Kruis W. Chronic inflammatory bowel disease and cancer. Hepatogastroenterology 2000;47:57-70."}],"container-title":["Archives of Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1194\/2081","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1194\/2082","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1194\/2081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T09:10:21Z","timestamp":1761210621000},"score":1,"resource":{"primary":{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/view\/1194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,30]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,9,30]]}},"URL":"https:\/\/doi.org\/10.46497\/archrheumatol.2021.8500","relation":{},"ISSN":["2618-6500"],"issn-type":[{"value":"2618-6500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,30]]}}}